世界のHIV関連リポジストロフィー症候群治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global HIV Associated Lipodystrophy Syndrome Treatment Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4315 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、HIV関連リポジストロフィー症候群治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（特定薬剤治療、化粧品矯正治療）、用途別市場規模（病院、専門医クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・HIV関連リポジストロフィー症候群治療の市場動向 ・企業の競争状況、市場シェア ・HIV関連リポジストロフィー症候群治療の種類別市場規模と予測2016-2027（特定薬剤治療、化粧品矯正治療） ・HIV関連リポジストロフィー症候群治療の用途別市場規模と予測2016-2027（病院、専門医クリニック、その他） ・HIV関連リポジストロフィー症候群治療の北米市場規模2016-2027（アメリカ、カナダ） ・HIV関連リポジストロフィー症候群治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・HIV関連リポジストロフィー症候群治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・HIV関連リポジストロフィー症候群治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・HIV関連リポジストロフィー症候群治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Gilead Sciences、Amgen、Abbott、AstraZeneca、AbbVie、GlaxoSmithKline、Alfa Wassermann SPA、Theratechnologies、Bristol-Myers Squibb） ・結論

Lipodystrophy syndrome groups together three clinical conditions characterized by abnormal body fat distribution: lipoatrophy, lipoaccumulation and a mixed syndrome. 

Market Analysis and Insights: Global HIV Associated Lipodystrophy Syndrome Treatment Market
The global HIV Associated Lipodystrophy Syndrome Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global HIV Associated Lipodystrophy Syndrome Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global HIV Associated Lipodystrophy Syndrome Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global HIV Associated Lipodystrophy Syndrome Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global HIV Associated Lipodystrophy Syndrome Treatment market.

Global HIV Associated Lipodystrophy Syndrome Treatment Scope and Market Size
HIV Associated Lipodystrophy Syndrome Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HIV Associated Lipodystrophy Syndrome Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Specific Drug Treatment
Cosmetic Corrective Treatment

Segment by Application
Hospital
Specialist Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Gilead Sciences
Amgen
Abbott
AstraZeneca
AbbVie
GlaxoSmithKline
Alfa Wassermann SPA
Theratechnologies
Bristol-Myers Squibb

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Specific Drug Treatment
1.2.3 Cosmetic Corrective Treatment
1.3 Market by Application
1.3.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Specialist Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Perspective (2016-2027)
2.2 HIV Associated Lipodystrophy Syndrome Treatment Growth Trends by Regions
2.2.1 HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 HIV Associated Lipodystrophy Syndrome Treatment Historic Market Share by Regions (2016-2021)
2.2.3 HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Regions (2022-2027)
2.3 HIV Associated Lipodystrophy Syndrome Treatment Industry Dynamic
2.3.1 HIV Associated Lipodystrophy Syndrome Treatment Market Trends
2.3.2 HIV Associated Lipodystrophy Syndrome Treatment Market Drivers
2.3.3 HIV Associated Lipodystrophy Syndrome Treatment Market Challenges
2.3.4 HIV Associated Lipodystrophy Syndrome Treatment Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top HIV Associated Lipodystrophy Syndrome Treatment Players by Revenue
3.1.1 Global Top HIV Associated Lipodystrophy Syndrome Treatment Players by Revenue (2016-2021)
3.1.2 Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Players (2016-2021)
3.2 Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by HIV Associated Lipodystrophy Syndrome Treatment Revenue
3.4 Global HIV Associated Lipodystrophy Syndrome Treatment Market Concentration Ratio
3.4.1 Global HIV Associated Lipodystrophy Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HIV Associated Lipodystrophy Syndrome Treatment Revenue in 2020
3.5 HIV Associated Lipodystrophy Syndrome Treatment Key Players Head office and Area Served
3.6 Key Players HIV Associated Lipodystrophy Syndrome Treatment Product Solution and Service
3.7 Date of Enter into HIV Associated Lipodystrophy Syndrome Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans

4 HIV Associated Lipodystrophy Syndrome Treatment Breakdown Data by Type
4.1 Global HIV Associated Lipodystrophy Syndrome Treatment Historic Market Size by Type (2016-2021)
4.2 Global HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Type (2022-2027)

5 HIV Associated Lipodystrophy Syndrome Treatment Breakdown Data by Application
5.1 Global HIV Associated Lipodystrophy Syndrome Treatment Historic Market Size by Application (2016-2021)
5.2 Global HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size (2016-2027)
6.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
6.2.1 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021)
6.2.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027)
6.2.3 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2027)
6.3 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
6.3.1 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021)
6.3.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027)
6.3.3 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2027)
6.4 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country
6.4.1 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021)
6.4.2 North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size (2016-2027)
7.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
7.2.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021)
7.2.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027)
7.2.3 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2027)
7.3 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
7.3.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021)
7.3.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027)
7.3.3 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2027)
7.4 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country
7.4.1 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021)
7.4.2 Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size (2016-2027)
8.2 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
8.2.1 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
8.3.1 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region
8.4.1 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size (2016-2027)
9.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
9.2.1 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021)
9.2.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027)
9.2.3 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2027)
9.3 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
9.3.1 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021)
9.3.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027)
9.3.3 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2027)
9.4 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country
9.4.1 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021)
9.4.2 Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size (2016-2027)
10.2 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type
10.2.1 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application
10.3.1 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country
10.4.1 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Gilead Sciences
11.1.1 Gilead Sciences Company Details
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.1.4 Gilead Sciences Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.1.5 Gilead Sciences Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.2.4 Amgen Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Abbott
11.3.1 Abbott Company Details
11.3.2 Abbott Business Overview
11.3.3 Abbott HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.3.4 Abbott Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.3.5 Abbott Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.4.4 AstraZeneca Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.4.5 AstraZeneca Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Details
11.5.2 AbbVie Business Overview
11.5.3 AbbVie HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.5.4 AbbVie Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.5.5 AbbVie Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.6.4 GlaxoSmithKline Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Alfa Wassermann SPA
11.7.1 Alfa Wassermann SPA Company Details
11.7.2 Alfa Wassermann SPA Business Overview
11.7.3 Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.7.4 Alfa Wassermann SPA Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.7.5 Alfa Wassermann SPA Recent Development
11.8 Theratechnologies
11.8.1 Theratechnologies Company Details
11.8.2 Theratechnologies Business Overview
11.8.3 Theratechnologies HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.8.4 Theratechnologies Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.8.5 Theratechnologies Recent Development
11.9 Bristol-Myers Squibb
11.9.1 Bristol-Myers Squibb Company Details
11.9.2 Bristol-Myers Squibb Business Overview
11.9.3 Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Introduction
11.9.4 Bristol-Myers Squibb Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
11.9.5 Bristol-Myers Squibb Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Specific Drug Treatment
Table 3. Key Players of Cosmetic Corrective Treatment
Table 4. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions (2016-2021)
Table 8. Global HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions (2022-2027)
Table 10. HIV Associated Lipodystrophy Syndrome Treatment Market Trends
Table 11. HIV Associated Lipodystrophy Syndrome Treatment Market Drivers
Table 12. HIV Associated Lipodystrophy Syndrome Treatment Market Challenges
Table 13. HIV Associated Lipodystrophy Syndrome Treatment Market Restraints
Table 14. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Players (2016-2021)
Table 16. Global Top HIV Associated Lipodystrophy Syndrome Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Associated Lipodystrophy Syndrome Treatment as of 2020)
Table 17. Ranking of Global Top HIV Associated Lipodystrophy Syndrome Treatment Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by HIV Associated Lipodystrophy Syndrome Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players HIV Associated Lipodystrophy Syndrome Treatment Product Solution and Service
Table 21. Date of Enter into HIV Associated Lipodystrophy Syndrome Treatment Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 24. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Type (2016-2021)
Table 25. Global HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Application (2016-2021)
Table 29. Global HIV Associated Lipodystrophy Syndrome Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 32. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021) (US$ Million)
Table 34. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 61. Gilead Sciences Company Details
Table 62. Gilead Sciences Business Overview
Table 63. Gilead Sciences HIV Associated Lipodystrophy Syndrome Treatment Product
Table 64. Gilead Sciences Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 65. Gilead Sciences Recent Development
Table 66. Amgen Company Details
Table 67. Amgen Business Overview
Table 68. Amgen HIV Associated Lipodystrophy Syndrome Treatment Product
Table 69. Amgen Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 70. Amgen Recent Development
Table 71. Abbott Company Details
Table 72. Abbott Business Overview
Table 73. Abbott HIV Associated Lipodystrophy Syndrome Treatment Product
Table 74. Abbott Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 75. Abbott Recent Development
Table 76. AstraZeneca Company Details
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca HIV Associated Lipodystrophy Syndrome Treatment Product
Table 79. AstraZeneca Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 80. AstraZeneca Recent Development
Table 81. AbbVie Company Details
Table 82. AbbVie Business Overview
Table 83. AbbVie HIV Associated Lipodystrophy Syndrome Treatment Product
Table 84. AbbVie Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 85. AbbVie Recent Development
Table 86. GlaxoSmithKline Company Details
Table 87. GlaxoSmithKline Business Overview
Table 88. GlaxoSmithKline HIV Associated Lipodystrophy Syndrome Treatment Product
Table 89. GlaxoSmithKline Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 90. GlaxoSmithKline Recent Development
Table 91. Alfa Wassermann SPA Company Details
Table 92. Alfa Wassermann SPA Business Overview
Table 93. Alfa Wassermann SPA HIV Associated Lipodystrophy Syndrome Treatment Product
Table 94. Alfa Wassermann SPA Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 95. Alfa Wassermann SPA Recent Development
Table 96. Theratechnologies Company Details
Table 97. Theratechnologies Business Overview
Table 98. Theratechnologies Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 99. Theratechnologies Recent Development
Table 100. Bristol-Myers Squibb Company Details
Table 101. Bristol-Myers Squibb Business Overview
Table 102. Bristol-Myers Squibb HIV Associated Lipodystrophy Syndrome Treatment Product
Table 103. Bristol-Myers Squibb Revenue in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021) & (US$ Million)
Table 104. Bristol-Myers Squibb Recent Development
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
List of Figures
Figure 1. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type: 2020 VS 2027
Figure 2. Specific Drug Treatment Features
Figure 3. Cosmetic Corrective Treatment Features
Figure 4. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Specialist Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. HIV Associated Lipodystrophy Syndrome Treatment Report Years Considered
Figure 9. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global HIV Associated Lipodystrophy Syndrome Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions: 2020 VS 2027
Figure 12. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Regions (2022-2027)
Figure 13. Global HIV Associated Lipodystrophy Syndrome Treatment Market Share by Players in 2020
Figure 14. Global Top HIV Associated Lipodystrophy Syndrome Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HIV Associated Lipodystrophy Syndrome Treatment as of 2020
Figure 15. The Top 10 and 5 Players Market Share by HIV Associated Lipodystrophy Syndrome Treatment Revenue in 2020
Figure 16. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Type (2016-2021)
Figure 17. Global HIV Associated Lipodystrophy Syndrome Treatment Revenue Market Share by Type (2022-2027)
Figure 18. North America HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type (2016-2027)
Figure 20. North America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2016-2027)
Figure 21. North America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Country (2016-2027)
Figure 22. United States HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type (2016-2027)
Figure 26. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2016-2027)
Figure 27. Europe HIV Associated Lipodystrophy Syndrome Treatment Market Share by Country (2016-2027)
Figure 28. Germany HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type (2016-2027)
Figure 36. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2016-2027)
Figure 37. Asia-Pacific HIV Associated Lipodystrophy Syndrome Treatment Market Share by Region (2016-2027)
Figure 38. China HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type (2016-2027)
Figure 46. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2016-2027)
Figure 47. Latin America HIV Associated Lipodystrophy Syndrome Treatment Market Share by Country (2016-2027)
Figure 48. Mexico HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Share by Type (2016-2027)
Figure 52. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Share by Application (2016-2027)
Figure 53. Middle East & Africa HIV Associated Lipodystrophy Syndrome Treatment Market Share by Country (2016-2027)
Figure 54. Turkey HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE HIV Associated Lipodystrophy Syndrome Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Gilead Sciences Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 58. Amgen Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 59. Abbott Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 60. AstraZeneca Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 61. AbbVie Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 63. Alfa Wassermann SPA Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 64. Theratechnologies Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in HIV Associated Lipodystrophy Syndrome Treatment Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---